This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Research experts at the Brookings Institution in Washington, D.C., analyzed the savings estimates provided by CMS for its drug price negotiations and compared them with the institution’s own estimates.
With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.
The Alzheimer disease treatment landscape is evolving with new FDA-approved antibody therapies and advancements in biomarker testing to enable earlier diagnosis and intervention.
I’m a doctor and epidemiologist, so you might expect me to be religious about preventative care: yearly visits to my primary care physician, that sort of thing. But I know we can’t prevent most disease and a lot of what we do in medicine doesn’t add value and sometimes even causes harm. So instead, I practice a seemingly radical but necessary idea for getting the best from medicine while avoiding excesses.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
Rachel Gross wants to clear up misconceptions about children and Covid-19. A pediatrician and population health researcher, she recalls a time four years ago when people didn’t think children could even contract the disease. Then, after accepting kids’ vulnerability to the virus, it was thought only adults could suffer from the myriad symptoms that persist or crop up post-infection, collectively known as long Covid.
Health IT giant Epic is pushing ahead rapidly to build out artificial intelligence technologies and generative AI features in its electronic health record software. | The goal, according to Epic executives, is to ease the documentation burden for clinicians, streamline charting and coding and bring evidence-based medical insights and research right to doctors' fingertips at the point of care.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
For years, Black Americans have been more likely to die of cancer than white Americans. There is a widespread belief that cancer screening — tests to detect hidden cancer — can reduce this Black-white disparity. While it is important to be attentive to racial disparities in health and health care, the belief in screening is misguided. More cancer screening primarily serves the interests of the health care system, not those of Black Americans.
The healthcare industry confronts a complex, double-barreled challenge as it tries to combat the recent deluge of dangerous and damaging cyberattacks. | Cyber resilience is the ability to recognize threats, respond to them, recover quickly and at scale. The clear goal: fending off attacks more efficiently, limiting damage and restoring normal operations with minimal impact to patients.
The study authors recommend that health care professionals are aware of the connections, notably in adolescent patients and those with moderate to severe psoriasis.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Megan Hanson was eight weeks pregnant in 2019 when she experienced a miscarriage — her sixth consecutive loss in as many years. It felt particularly cruel after a second IVF transfer. She and her husband, Ben Burnham, were devastated, physically and financially drained — and deeply frustrated by the lack of answers or support for people like them who had experienced recurrent miscarriages.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Last week, a mask ban in Nassau County, New York was signed into law. If I lived just 60 miles east of my New Jersey town, I would be under threat of a fine or jail time every time I left the house. I’ve been masking consistently in public since 2020, when the Covid-19 pandemic began, because I have a kidney transplant and will take immunosuppressant medication for the rest of my life.
Employers are actively seeking out alternatives to curb rising health benefit costs by sidestepping traditional carriers, a new report from Brighton Health Plan Solutions shows. | A new report highlights a business opportunity for providers and health systems to engage in direct contracting.
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In a Phase 3 trial that lasted over three years, people with pre-diabetes taking Zepbound had a 93% lower risk of progressing to diabetes compared with people on placebo, Lilly said Tuesday.
The upward trajectory of Medicare Advantage (MA) enrollment is likely to become an issue for hospitals and other healthcare providers forced to contend with plans’ prior authorization requirements | Prior authorization burdens and "a challenging contract negotiation season" on the horizon are likely headwinds for providers, and hospitals in particular, according to a recent report.
Private equity firms are sucking the resources out of America’s hospitals and nursing homes, and feeding on doctors to generate profits. These firms — which pool funds from wealthy investors and are exempt from many of the regulations and disclosure requirements that apply to other types of investments — have spent a half-trillion dollars since 2018 buying up medical resources.
Steve Anderson, president and CEO of the National Association of Chain Drug Stores (NACDS), discusses memorable moments from this year's NACDS Total Store Expo.
Peter Orszag was instrumental in crafting the Affordable Care Act. Now, he wants federal antitrust authorities to ease up on their sharp scrutiny of health care transactions that he acknowledges the law has encouraged — and that make a lot of money for his investment bank. Orszag’s comments, made last week on TV, reveal how policymakers can end up profiting from the laws they help create.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content